PLI Milestone: Venus Remedies Secures Incentive for FY 2024 - 25
Securing 75% of the eligible FY 2024–25 PLI incentive, Venus Remedies reaffirms its manufacturing excellence, consistent performance, and commitment to strengthening India’s pharmaceutical ecosystem
PLI Milestone: Venus Remedies Secures Incentive for FY 2024–25
We are proud to share yet another extraordinary achievement in our journey. The company has received its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals.
It is not just any amount, but 75% of the total eligible incentive for FY 2024–25 that counts for ₹11.77 Crore. This marks another step forward in strengthening our manufacturing capabilities and operational performance.
What is the PLI Scheme
PLI is India’s performance-linked manufacturing program: eligible companies receive incentives tied to incremental sales of goods manufactured in India. The core idea is simple: reward measurable output, not intent. The scheme was launched in 2020 and expanded over time to cover 14 sectors.
Under the Atmanirbhar Bharat campaign, the Indian government launched the Production Linked Incentive (PLI) scheme to boost domestic manufacturing, attract investments, and increase exports.
Covering 14 key sectors, including pharmaceuticals, the scheme aims to encourage manufacturers to expand operations in India.
Why This Matters
As a matter of fact, PLI is granted only after a company delivers audited performance against strict thresholds. It signals that Venus Remedies has demonstrated consistency and quality in its investment, manufacturing, production, and sales.
Additionally, the scheme fund puts us in a position where we can strengthen our manufacturing capability and boost export business.
This ‘more than half of the fund’ achievement has boosted our credibility as it has earned wide media coverage in Express Pharma, The Indian Practitioner, Medical Dialogues, and more.
What’s Next?
Under the leadership of Mr. Saransh Chaudhary, President – Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre, PLI 2.0 positions us to invest in:
- Expanding manufacturing capacity for a reliable supply.
- Upgrading global technology for complex injectable manufacturing.
- Maintain and elevate quality healthcare.
- Self-reliant pharmaceutical ecosystem.
- Generating employment to meet manufacturing requirements.
